Humacyte (HUMA) Long-Term Deferred Tax (2020)

Humacyte (HUMA) reported Long-Term Deferred Tax of $49000.0 for Q4 2020.

Humacyte (HUMA) Long-Term Deferred Tax (2020) Analysis & Trends

Humacyte (HUMA) has 1 years of Long-Term Deferred Tax data on file, last reported at $49000.0 in Q4 2020.

Long-Term Deferred Tax for Q4 2020 came in at $49000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $49000.0 (changed N/A YoY), and the FY2020 annual result was $49000.0, changed N/A from the prior year.
Long-Term Deferred Tax steadied at $49000.0 in Q4 2020 per HUMA's latest filing.
Over five years, Long-Term Deferred Tax peaked at $49000.0 in Q4 2020 and troughed at $49000.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Humacyte	267.09 Mn	218.55 Mn	-1.54 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2020	49,000.00